Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation.

Lonze BE, Zachary AA, Magro CM, Desai NM, Orandi BJ, Dagher NN, Singer AL, Carter-Monroe N, Nazarian SM, Segev DL, Streiff MB, Montgomery RA.

Am J Transplant. 2014 Feb;14(2):459-65. doi: 10.1111/ajt.12540. Epub 2014 Jan 8.

2.

Report of the inefficacy of eculizumab in two cases of severe antibody-mediated rejection of renal grafts.

Burbach M, Suberbielle C, Brochériou I, Ridel C, Mesnard L, Dahan K, Rondeau E, Hertig A.

Transplantation. 2014 Nov 27;98(10):1056-9. doi: 10.1097/TP.0000000000000184.

PMID:
24839895
3.

Efficacy of Eculizumab Therapy for Atypical Hemolytic Uremic Syndrome Recurrence and Antibody-Mediated Rejection Progress After Renal Transplantation With Preformed Donor-Specific Antibodies: Case Report.

Yamamoto T, Watarai Y, Futamura K, Okada M, Tsujita M, Hiramitsu T, Goto N, Narumi S, Takeda A, Kobayashi T.

Transplant Proc. 2017 Jan - Feb;49(1):159-162. doi: 10.1016/j.transproceed.2016.10.013.

PMID:
28104125
4.

Living donor renal transplantation in patients with antiphospholipid syndrome: A case report.

Choi JY, Jung JH, Shin S, Kim YH, Han DJ.

Medicine (Baltimore). 2016 Nov;95(46):e5419.

5.

Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab.

Shapira I, Andrade D, Allen SL, Salmon JE.

Arthritis Rheum. 2012 Aug;64(8):2719-23. doi: 10.1002/art.34440.

6.

Plasmapheresis in a patient with antiphospholipid syndrome before living-donor kidney transplantation: a case report.

Sofue T, Hayashida Y, Hara T, Kawakami K, Ueda N, Kushida Y, Inui M, Dobashi H, Kakehi Y, Kohno M.

BMC Nephrol. 2014 Oct 15;15:167. doi: 10.1186/1471-2369-15-167.

7.

Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes.

Canaud G, Kamar N, Anglicheau D, Esposito L, Rabant M, Noël LH, Guilbeau-Frugier C, Sberro-Soussan R, Del Bello A, Martinez F, Zuber J, Rostaing L, Legendre C.

Am J Transplant. 2013 Aug;13(8):2179-85. doi: 10.1111/ajt.12319. Epub 2013 Jun 13.

8.

Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients.

Stegall MD, Diwan T, Raghavaiah S, Cornell LD, Burns J, Dean PG, Cosio FG, Gandhi MJ, Kremers W, Gloor JM.

Am J Transplant. 2011 Nov;11(11):2405-13. doi: 10.1111/j.1600-6143.2011.03757.x. Epub 2011 Sep 22. Erratum in: Am J Transplant. 2013 Jan;13(1):241.

9.

Eculizumab in renal transplantation.

Legendre C, Sberro-Soussan R, Zuber J, Rabant M, Loupy A, Timsit MO, Anglicheau D.

Transplant Rev (Orlando). 2013 Jul;27(3):90-2. doi: 10.1016/j.trre.2013.04.002. Epub 2013 Jun 7. Review.

PMID:
23747093
10.

Prevention and treatment of atypical haemolytic uremic syndrome after kidney transplantation.

Okumi M, Tanabe K.

Nephrology (Carlton). 2016 Jul;21 Suppl 1:9-13. doi: 10.1111/nep.12776. Review.

PMID:
26988663
11.

Eculizumab Induces Sustained Remission in a Patient With Refractory Primary Catastrophic Antiphospholipid Syndrome.

Zikos TA, Sokolove J, Ahuja N, Berube C.

J Clin Rheumatol. 2015 Sep;21(6):311-3. doi: 10.1097/RHU.0000000000000290.

PMID:
26267719
12.

Ten-yr renal allograft survival of patients with antiphospholipid antibody syndrome.

Vaidya S.

Clin Transplant. 2012 Nov-Dec;26(6):853-6. doi: 10.1111/j.1399-0012.2012.01625.x. Epub 2012 Apr 16.

PMID:
22507396
13.

Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort.

Mallett A, Hughes P, Szer J, Tuckfield A, Van Eps C, Cambell SB, Hawley C, Burke J, Kausman J, Hewitt I, Parnham A, Ford S, Isbel N.

Intern Med J. 2015 Oct;45(10):1054-65. doi: 10.1111/imj.12864.

PMID:
26247170
14.

Eculizumab and renal transplantation in a patient with CAPS.

Lonze BE, Singer AL, Montgomery RA.

N Engl J Med. 2010 May 6;362(18):1744-5. doi: 10.1056/NEJMc0910965. No abstract available.

15.

Eculizumab and splenectomy as salvage therapy for severe antibody-mediated rejection after HLA-incompatible kidney transplantation.

Orandi BJ, Zachary AA, Dagher NN, Bagnasco SM, Garonzik-Wang JM, Van Arendonk KJ, Gupta N, Lonze BE, Alachkar N, Kraus ES, Desai NM, Locke JE, Racusen LC, Segev DL, Montgomery RA.

Transplantation. 2014 Oct 27;98(8):857-63. doi: 10.1097/TP.0000000000000298.

PMID:
25121475
16.

Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases.

Nester CM, Brophy PD.

Curr Opin Pediatr. 2013 Apr;25(2):225-31. doi: 10.1097/MOP.0b013e32835df4a3. Review.

PMID:
23486421
17.

Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report.

Xie L, Nester CM, Reed AI, Zhang Y, Smith RJ, Thomas CP.

Transplant Proc. 2012 Dec;44(10):3037-40. doi: 10.1016/j.transproceed.2012.07.141.

PMID:
23195022
18.

Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation.

Hadaya K, Ferrari-Lacraz S, Fumeaux D, Boehlen F, Toso C, Moll S, Martin PY, Villard J.

Am J Transplant. 2011 Nov;11(11):2523-7. doi: 10.1111/j.1600-6143.2011.03696.x. Epub 2011 Aug 10.

19.

De novo thrombotic microangiopathy following simultaneous pancreas and kidney transplantation managed with eculizumab.

Shochet L, Kanellis J, Simpson I, Ta J, Mulley W.

Nephrology (Carlton). 2017 Feb;22 Suppl 1:23-27. doi: 10.1111/nep.12936. Review.

PMID:
28176480
20.

Two cases of kidney transplantation-associated thrombotic microangiopathy successfully treated with eculizumab.

Ikeda T, Okumi M, Unagami K, Kanzawa T, Sawada A, Kawanishi K, Omoto K, Ishida H, Tanabe K.

Nephrology (Carlton). 2016 Jul;21 Suppl 1:35-40. doi: 10.1111/nep.12768.

PMID:
26970541

Supplemental Content

Support Center